Loading icon
Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

3471 - 3480 of 3734 results found

School closures during COVID-19: an overview of systematic reviews

Date
Friday, March 31, 2023 - 4:00 AM
Description
CONCLUSIONS: School closures during COVID-19 had both positive and negative impacts. We found a large number of SRs and primary studies. However, confidence in the SRs was mostly low to very low, and the certainty of evidence was also mostly very low

SCI Thrive: Impact of a peer-led online self-management program

Date
Friday, March 31, 2023 - 4:00 AM
Description
CONCLUSION: SCI Thrive is a highly accessible program for individuals with SCI and shows promise for improving self-efficacy. Strategies to increase engagement should be added to maximize benefits. Measurement tools may have been impacted by COVID-19

Speleomycology of Air in Stopića Cave (Serbia)

Date
Friday, March 31, 2023 - 4:00 AM
Description
Fungi can colonize organic matter present in subterranean sites and have a significant role as dwellers in different microniches of cave habitats. In order to analyze the content of airborne fungal propagules in different parts of "Stopića Cave," a

Severe systemic inflammation mimicking TAFRO syndrome following COVID-19

Date
Friday, March 31, 2023 - 4:00 AM
Description
TAFRO syndrome is a rare systemic inflammatory disease. Its pathogenesis mainly involves excessive cytokine secretion and autoimmune dysfunction. Although its etiology is unclear, some viral infections have been reported to cause it. Here, we report

Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial

Date
Friday, March 31, 2023 - 4:00 AM
Description
BACKGROUND: Young women in sub-Saharan Africa continue to bear a high burden of HIV infection. Combination anti-HIV monoclonal antibodies are a potential HIV prevention technology that could overcome adherence challenges of daily oral pre-exposure